News

Biogen to Webcast from the Alzheimer's Association International Conference (AAIC) July 14, 2026

Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Biogen to Report Second Quarter 2026 Financial Results July 29, 2026

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Biogen Announces Webcast of Annual Meeting of Stockholders

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease